Literature DB >> 17475211

Effective delivery with enhanced translational activity synergistically accelerates mRNA-based transfection.

F T Zohra1, E H Chowdhury, S Tada, T Hoshiba, T Akaike.   

Abstract

mRNA instead of DNA provides a new and attractive approach for gene therapy and genetic vaccination. Current technologies for mRNA delivery are based on cationic lipids with DOTAP being the most efficient one. We previously reported on the synthesis of an inorganic-organic hybrid carrier by embedding inorganic nano-particles of carbonate apatite onto liposomal carrier DOTAP and demonstrated its high transfection potency of luciferase mRNA both in mitotic and non-mitotic cells. Here we show that in addition to the carrier design for effective endocytosis and release of mRNA to the cytoplasm, enhancement of mRNA translation efficiency is a prerequisite for maximum protein expression. We used the modified cap analog (ARCA) during in vitro transcription of luciferase DNA for proper cap orientation and demonstrated that transfection with ARCA-mRNA resulted in higher protein expression than the mRNA with usual cap structure for both DOTAP and DOTAP-apatite complex. Secondly, exogenous poly(A) was co-delivered with mRNA by the DOTAP-apatite, resulting in very significant expression compared to mRNA delivery only. Finally, when combined both of the effects of smart carrier and the modifications at mRNA translational level, a notable enhancement (100 times) was achieved as compared to the existing DOTAP-based liposome technology. Our findings, therefore, unveiled a novel approach that an effective delivery system can be developed by the improvement of the gene expression level in combination with the enhancement of the carrier potency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17475211     DOI: 10.1016/j.bbrc.2007.04.059

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

1.  Design, Assembly, Production, and Transfection of Synthetic Modified mRNA.

Authors:  Sanders Oh; John A Kessler
Journal:  Methods       Date:  2017-11-07       Impact factor: 3.608

Review 2.  Genome Editing with mRNA Encoding ZFN, TALEN, and Cas9.

Authors:  Hong-Xia Zhang; Ying Zhang; Hao Yin
Journal:  Mol Ther       Date:  2019-01-25       Impact factor: 11.454

Review 3.  Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.

Authors:  S Guan; J Rosenecker
Journal:  Gene Ther       Date:  2017-01-17       Impact factor: 5.250

Review 4.  Developing mRNA-vaccine technologies.

Authors:  Thomas Schlake; Andreas Thess; Mariola Fotin-Mleczek; Karl-Josef Kallen
Journal:  RNA Biol       Date:  2012-10-12       Impact factor: 4.652

Review 5.  Engineering the Delivery System for CRISPR-Based Genome Editing.

Authors:  Zachary Glass; Matthew Lee; Yamin Li; Qiaobing Xu
Journal:  Trends Biotechnol       Date:  2018-01-02       Impact factor: 19.536

Review 6.  The Past, Present, and Future of Non-Viral CAR T Cells.

Authors:  Alex Moretti; Marianna Ponzo; Charles A Nicolette; Irina Y Tcherepanova; Andrea Biondi; Chiara F Magnani
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

Review 7.  The legacy of mRNA engineering: A lineup of pioneers for the Nobel Prize.

Authors:  Miroslaw Janowski; Anna Andrzejewska
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-13       Impact factor: 10.183

8.  Biomaterials for mRNA delivery.

Authors:  Mohammad Ariful Islam; Emma K G Reesor; Yingjie Xu; Harshal R Zope; Bruce R Zetter; Jinjun Shi
Journal:  Biomater Sci       Date:  2015-08-17       Impact factor: 6.843

9.  Characterization of liposomes for cancer cell transfection.

Authors:  Svetlana A Tatarkova; Satvinder Khaira
Journal:  Open Biomed Eng J       Date:  2007-10-26

10.  In vitro Study of a Novel Stent Coating Using Modified CD39 Messenger RNA to Potentially Reduce Stent Angioplasty-Associated Complications.

Authors:  Meike-Kristin Abraham; Andrea Nolte; Rebekka Reus; Andreas Behring; Diane Zengerle; Meltem Avci-Adali; Jan David Hohmann; Karlheinz Peter; Christian Schlensak; Hans Peter Wendel; Stefanie Krajewski
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.